Company Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
The company’s pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.
It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease.
In addition, the company’s preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor.
It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases.
Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
| Country | United States |
| Founded | 2015 |
| IPO Date | Mar 15, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 577 |
| CEO | Terry Rosen |
Contact Details
Address: 3928 Point Eden Way Hayward, California 94545 United States | |
| Phone | 510 694 6200 |
| Website | arcusbio.com |
Stock Details
| Ticker Symbol | RCUS |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001724521 |
| CUSIP Number | 03969F109 |
| ISIN Number | US03969F1093 |
| Employer ID | 47-3898435 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Terry J. Rosen Ph.D. | Co-Founder, Chairman and Chief Executive Officer |
| Dr. Juan Carlos Jaen Ph.D. | Co- Founder and President |
| Robert C. Goeltz II | Principal Financial Officer and Chief Financial Officer |
| Jennifer A. Jarrett M.B.A. | Chief Operating Officer |
| Dr. Dimitry S.A. Nuyten M.D., Ph.D. | Chief Medical Officer |
| Dr. K. Christopher Garcia Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Alexander Azoy CPA | Vice President of Finance and Principal Accounting Officer |
| Dr. Jonathan Yingling Ph.D. | Chief Scientific Officer |
| Pia Eaves | Vice President of Investor Relations and Strategy |
| Carolyn C. Tang J.D. | General Counsel and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 17, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | 8-K | Current Report |
| Oct 24, 2024 | 8-K | Current Report |
| Oct 23, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 17, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Aug 27, 2024 | 8-K | Current Report |
| Aug 8, 2024 | 10-Q | Quarterly Report |